Market Overview

J.P. Morgan Reiterates Overweight Rating on The Cooper Companies

Related COO
Top 4 Mid-Cap Stocks In The Medical Instruments & Supplies Industry With The Highest Profit Margin
What Analysts Are Saying About Cooper Companies

In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on The Cooper Companies (NYSE: COO).

J.P. Morgan noted, “Cooper released an 8K on Friday afternoon highlighting an amendment to its license agreement with CIBA Vision (a division of NOVN, covered by JPMA Alexandra Hauber-Schuele, rated Neutral). Recall that Cooper currently pays Ciba an 8% royalty on all silicone hydrogel lens sales, which dates back to 2007. Cooper, along with J&J's Vistakon unit and Bausch & Lomb (private) were each found to infringe Ciba's Nicholson patents over the past decade, and J&J settled with Ciba back in January of 2011. Cooper indicated in its 8K filing that it has amended the existing patent license agreement, effective January 1, 2013. While the new royalty payment has not been made public, we can assume it is lower given the upward revisions to guidance.”

The Cooper Companies closed on Friday at $92.86.

Latest Ratings for COO

Mar 2015BMO CapitalMaintainsOutperform
Mar 2015JP MorganMaintainsOverweight
Mar 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for COO
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings


Related Articles (COO)

Around the Web, We're Loving...